By Olivia Nerpouni

Today, breakthrough ideas often fail not because they lack merit, but because the systems around them are fragmented. For physician-entrepreneur Dr. Violet Zahedi, that reality has become both a professional challenge and a personal mission. With the launch of Xivius, her latest venture, she hopes to close the gaps that stall world-changing ideas by building a fully integrated ecosystem where expertise and infrastructure work together from the earliest stages.

Born and raised in Gorgan, Iran, Dr. Zahedi’s earliest years in medicine were kickstarted by a desire to solve practical problems for patients. She saw that clinical care, however essential, was only one piece of a much larger puzzle. Breakthrough treatments and technological advances mattered, but equally important were the systems that determined whether those innovations reached the people who needed them most.

This early awareness shaped her career from that moment onward. From working within Iran’s healthcare system to taking on roles in clinical research and the pharmaceutical sector in Europe, Dr. Zahedi gathered invaluable insight into the structural and regulatory challenges that come with medical innovation. By the time she founded her first company, she had lived and worked across multiple countries, accumulating a global perspective on what it takes to move ideas from concept to market.

In 2023, Dr. Zahedi founded Synamics Therapeutics in Denmark, a biotech company at the cutting edge of precision medicine. Its mission was to use artificial intelligence to predict the progression of cancer and design treatments for those changes. Cancer, one of the most formidable challenges in medicine, is rarely static. It mutates, evolves, and often resists treatment. By combining predictive modeling with precision therapies, Synamics sought to outpace the disease itself.

The company’s trajectory was remarkable. Within its first year, Synamics secured funding at the concept stage, an achievement attained by less than 1% of startups. That early capital allowed the company to expand operations, eventually relocating its headquarters to Los Angeles and building partnerships with cancer research centers across the United States. But while Synamics grew, Dr. Zahedi noticed a troubling pattern repeating across the startup landscape. She saw talented founders with transformative ideas stall out because they could not access the right capital or infrastructure at the right time. The result was Xivius, a venture and investment ecosystem meant to connect big ideas with everything they need to succeed. Xivius is able to integrate strategy, execution, and funding into a single framework.

At the concept stage, Xivius works closely with founders to refine ideas, validate viability, and map out infrastructure needs. The company then draws from its network of consultants, operators, and advisors to ensure execution does not rest solely on the founder’s shoulders. Once a strong foundation is in place, Xivius activates its curated investor circle to align capital with the venture’s growth trajectory. As companies scale, Xivius provides cross-border strategies, partnerships, and market entry support, making global expansion less daunting and more natural.

Unlike traditional accelerators or funds that cast wide nets, Xivius is highly selective. Dr. Zahedi emphasizes that the platform is not about supporting “every good idea,” but about finding rare, category-defining ideas that thrive within its ecosystem. Her evaluation framework is simple yet rigorous. She first looks at a founder’s vision – does the idea have the potential to move an industry forward, not just compete within it? Then her team discusses scalability – can it grow beyond a niche to redefine markets or create new categories? Lastly, Dr. Zahedi assesses fit – does the idea align with what Xivius does best, connecting strategy, execution, and capital into one system? This process ensures that the ventures Xivius supports are positioned for sustainable, global impact.

Though Xivius is set to formally launch in Q1 2026, the groundwork is already underway. The company is already onboarding its first circle of investors and thought leaders, preparing to expand across sectors ranging from life sciences to emerging technologies. Looking a few years ahead, Dr. Zahedi has a clear picture of what success means for Xivius. It is not just financial metrics or unicorn valuations, but cultural impact. For Dr. Zahedi, Xivius is a movement to redefine innovation itself. By fostering trust, collaboration, and systemic integration, she sees a world where the next generation of breakthroughs will not be hindered by structural barriers.

With the official launch approaching, anticipation around Xivius is growing. The company is already attracting interest from influential leaders and investors, and the formation of the XVS Club marks an important step in building a community of aligned stakeholders. “I couldn’t be more excited,” Dr. Zahedi says. Just as medicine requires treating patients physically, she sees innovation as a living organism that needs care. By creating an ecosystem where every critical element is connected, she is changing what it takes to bring transformative ideas into the world.

The official launch may be months away, but Xivius represents how the most transformative ideas will be nurtured and brought into the world where they can change lives.

For more information on Xivius, visit https://www.xivius.com/.